Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| §112 only | 1 (17%) |
| No statute on record | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 65.8% | +47.7% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 67.7% | +39.0% |
| PARISI, JESSICA DANIELLE | 1 | 79.8% | +28.0% |
| O'NEILL, MARISOL ANN | 1 | 52.2% | +64.7% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.7% |
| SALVOZA, M FRANCO G | 1 | 69.0% | +29.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 60d overdue |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 32d overdue |
| 17787900 | METHOD FOR IDENTIFYING REGULATORY ELEMENTS CONFORMATIONALLY | PARISI, JESSICA DANIELLE | 32d overdue |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | SALVOZA, M FRANCO G | 17d overdue |
| 18955455 | METHODS OF RECOMBINANT ADENO-ASSOCIATED VIRUS KIDNEY ADMINISTRATION | SPENCE, JENNIFER SUZANNE | 14d |
| 17620557 | PRODUCTION OF VECTORS USING PHAGE ORIGIN OF REPLICATION | HOLLAND, PAUL J | 16d |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1684 | 1 |
| 1656 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18955455 | METHODS OF RECOMBINANT ADENO-ASSOCIATED VIRUS KIDNEY ADMINISTRATION | SPENCE, JENNIFER SUZANNE | 1633 | §112 | Non-Final OA | 14d | Pending | Nov 21, 2024 |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103 | Non-Final OA | 32d overdue | Pending | Feb 02, 2023 |
| 17787900 | METHOD FOR IDENTIFYING REGULATORY ELEMENTS CONFORMATIONALLY | PARISI, JESSICA DANIELLE | 1684 | Other | Non-Final OA | 32d overdue | Pending | Dec 06, 2022 |
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 1633 | §103 | Non-Final OA | 60d overdue | Pending | Aug 04, 2022 |
| 17620557 | PRODUCTION OF VECTORS USING PHAGE ORIGIN OF REPLICATION | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | 16d | Pending | Dec 17, 2021 |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | SALVOZA, M FRANCO G | 1672 | Other | Non-Final OA | 17d overdue | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial